Navigation Links
Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
Date:10/21/2008

Lilly to Pay Amylin $125 Million and Extend $165 Million Line of Credit to

Amylin

SAN DIEGO and INDIANAPOLIS, Oct. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced they have entered into a product supply agreement for exenatide once weekly, a development compound that, if approved, would become the first once weekly therapy to treat type 2 diabetes. Under terms of the agreement, Lilly will make an initial cash payment of $125 million to Amylin, and Amylin will supply product for sales in the U.S. and to Lilly for sales outside of the U.S. In addition to the $125 million upfront payment, Lilly will reimburse Amylin for its share of the more than $500 million capital investment in the West Chester, Ohio facility through the cost of goods sold for exenatide once weekly.

As part of the overall supply arrangement, Lilly will make available to Amylin a $165 million line of credit that Amylin can draw upon beginning in the fourth quarter of 2009 through the second quarter of 2011. Any debt from the credit facility will be due three years from the date that the full amount has been drawn or the second quarter of 2014, whichever occurs first.

"Amylin and Lilly continue to strengthen our exenatide alliance, building on the success of BYETTA(R), our first-in-class medicine that has been used by approximately 1 million patients worldwide," said John C. Lechleiter, Ph.D., Lilly's president and chief executive officer. "With this agreement, we acknowledge Amylin's commitment in making this important investment to build critical manufacturing capacity."

"The state-of-the art manufacturing facility in Ohio is readying for full-scale commercial manufacturing of exenatide once weekly," said Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals. "This agreement strengthens our balance sheet and provides us with financial flexibility in the future, while moving us closer to our goal of bringing exenatide once weekly to patients as quickly as possible."

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 2,000 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.

About Lilly

Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help healthcare professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients. For more information about Lilly's current diabetes products visit http://www.lillydiabetes.com.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

This press release contains forward-looking statements about Amylin and Lilly. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that BYETTA and the revenues generated from BYETTA or exenatide once weekly may be affected by competition; unexpected new data; safety and technical issues; exenatide once weekly may not be submitted in a timely manner or receive regulatory approval; or manufacturing and supply issues including risks that the manufacturing facility mentioned in this press release will not be completed in a timely manner or receive regulatory approval. The potential for BYETTA or, if approved, exenatide once weekly may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the commercialization of pharmaceutical products. These and additional risks and uncertainties are described more fully in Amylin's and Lilly's most recent SEC filings including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Amylin and Lilly undertake no duty to update these forward-looking statements.

P-LLY


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... ... May 19, 2016 , ... Anton Paar USA, located in Ashland, Virginia is ... complete. The new structure adds a third office building to the current facilities. ... 2.4 acres of land, along with office space adjacent to the previous main building. ...
(Date:5/19/2016)... Regen BioPharma, Inc ... announced today initiation of a preclinical development program ... cancer immunotherapeutic product leveraging its NR2F6 immunological checkpoint. ... generation of cord blood derived killer cells whose ... product in development will be a "universal donor" ...
(Date:5/18/2016)... The Biotech industry continues to face ... there are no opportunities ahead. Today, ActiveWallSt.com has on its ... THLD ), Seattle Genetics Inc. (NASDAQ: SGEN ), ... (NASDAQ: OPHT ). Sign up now to receive ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s shares gained 0.68%, ...
(Date:5/18/2016)... ... May 18, 2016 , ... Ryan Benton was diagnosed ... expectancy in the late teens to early twenties. DMD is a relatively common progressive ... the age of 22, Benton’s condition was critical. He met with the founder of ...
Breaking Biology Technology:
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):